GENFIT, whose shares are admitted to trading on Euronext Paris and NASDAQ, has acquired the entire capital of Versantis, a Swiss-based biopharmaceutical company aimed at meeting the growing medical needs in the field of liver diseases.
The acquisition of Versantis is part of GENFIT’s strategy to become a global leader in Acute-on-Chronic Liver Failure (ACLF) and is another key step in the execution of this strategy. With the signing of this agreement, GENFIT will also expend its product portfolio to other liver diseases with significant unmet medical needs through other products developed by Versantis.
The Linklaters team was lead from Paris by partner Pierre Thomet, counsel Julien Bourmaud-Danto and associate Géraldine Gonzalvez within the Corporate/M&A practice, by Capital Markets partner Bertrand Sénéchal and associate Antoine Galvier and by Employment Law partner Géric Clomes and associate Valentine Charrier.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
